This study investigates the use of FDA-approved targeted therapies in patients with advanced cancer that have specific genetic changes in their tumors. These genetic changes, known as genomic variants, can affect how cancer cells grow and respond to treatments. The purpose of this study is to describe the safety and effectiveness of these therapies in real-world settings, focusing on patients whose tumors have genomic variants that are known to be targets for specific drugs.
Participants in the study will receive targeted anticancer drugs that are already commercially available and approved by the FDA. These drugs are provided by pharmaceutical companies collaborating with the study. The study is non-randomized, meaning all participants will receive a treatment based on their tumor's specific genomic variant. The study will also look at the molecular tests used by doctors to choose treatments and may help develop ideas for future research.
- Who can participate: Adults and children aged 12 and older with advanced solid tumors, multiple myeloma, or B cell non-Hodgkin lymphoma can participate. They must have a tumor with a genomic profile that may benefit from one of the FDA-approved drugs in the study and have measurable disease.
- Study details: Participants will take part in a study using FDA-approved targeted anticancer drugs based on their tumor's genetic profile. They will undergo molecular testing to determine eligibility and will take the assigned medication while undergoing regular health assessments to monitor safety and effectiveness.